Paclitaxel + Carboplatin

Search with Google Search with Bing

Information
Drug Name
Paclitaxel + Carboplatin
Description
Entry(CIViC)
CIViC
[No Data.]
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
In this phase II trial (metastatic melanoma), beva... VEGFA VEGFA UNDEREXPRESSION Sensitivity true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT03168880 Active, not recruiting Phase 3 A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer April 2010 November 30, 2025
NCT02453282 Active, not recruiting Phase 3 Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) July 21, 2015 December 31, 2024
NCT02542293 Active, not recruiting Phase 3 Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) November 3, 2015 December 31, 2024
NCT03003962 Active, not recruiting Phase 3 Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) January 2, 2017 June 3, 2026
NCT00298415 Completed Phase 3 Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) March 2006 December 2011
NCT00516724 Completed Phase 1 Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel June 22, 2007 April 11, 2024
NCT02658214 Completed Phase 1 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors April 28, 2016 November 14, 2019
NCT00254891 Terminated Phase 3 Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer November 2005 July 2008